Abstracts tagged "SLE"

Abstract Number: 667 • 2019 ACR/ARP Annual Meeting
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Nathaniel Harris¹, Amanda Eudy ², Megan Clowse ², Lisa Criscione-Schreiber ², Jayanth Doss ², Rebecca Sadun ², Jennifer Rogers ² and Kai Sun ², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham
Background/Purpose: We have developed a new conceptual model that characterizes lupus into subtypes based on physician- and patient-reported measures: Type 1 is assessed by the…
Abstract Number: 975 • 2019 ACR/ARP Annual Meeting
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Abhimanyu Amarnani¹, Ramile Dilshat ², Nikita Malakhov ³, Brian Ghezelaiagh ⁴, Chongmin Huan ¹, Erna Magnusdottir ², Eirikur Steingrimsson ² and Christopher Roman ¹, ¹SUNY Downstate Medical Center, Brooklyn, ²University of Iceland Biomedical Center, Reykjavik, Iceland, ³SUNY Downstate Medical Center, New York Presbyterian-Weill Cornell Medical Center, Brooklyn, ⁴SUNY Downstate Medical Center, Stony Brook University, Brooklyn
Background/Purpose: Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated…
Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Sarit Sekhar Pattanaik¹, Ankita Singh ², Shilpa Venkataraman ³, Ramnath Misra ⁴, Vinita Agrawal ² and Amita Aggarwal ⁵, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…
Abstract Number: 1941 • 2019 ACR/ARP Annual Meeting
Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Jing Cui¹, Soumya Raychaudhuri ², Cameron Speyer ², Susan Malspeis ², Hongshu Guan ³, Xinyi Liu ², Jessica Williams ², Emma Davenport ⁴, Rachel Knevel ⁵, Elizabeth Karlson ² and Karen Costenbader ², ¹Brigham Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Sanger Institute, Cambridge, United Kingdom, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have previously reported that current smoking (or having recently quit within 4 years) was associated with elevated risk of SLE, in particular anti-dsDNA+…
Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Iris Lee¹, Brigid Marshall ¹, Prabha Ranganathan ², Seth Eisen ³, Rithwick Rajagopal ¹, Alfred Kim ³ and Tingting Li ¹, ¹Washington University in St Louis, St Louis, ²Washington University in St Louis, St Louis, MO, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…
Abstract Number: 668 • 2019 ACR/ARP Annual Meeting
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
J. Patricia Dhar¹, Louis Saravolatz ² and Susan Szpunar ³, ¹Wayne State University, Bloomfield Hills, MI, ²Ascension St. John Hospital and Wayne State University, Grosse Pointe Woods, MI, ³Ascension St. John Hospital Hospital, Grosse Pointe Woods, MI
Background/Purpose: Women with SLE are at increased risk for cervical neoplasia likely because of infection with high risk (HR) HPV and thus should be considered…
Abstract Number: 1016 • 2019 ACR/ARP Annual Meeting
Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis
Wei Liu¹, Yuanhao Wu ¹ and Wenjia Zhao ¹, ¹First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a common autoimmune disease. The occurrence and development of SLE is a result of multiple factors, but its exact…
Abstract Number: 1576 • 2019 ACR/ARP Annual Meeting
Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis
Tatiana Costa Pires¹, Raquel Caparrós-Ruiz ² and David A Isenberg ³, ¹Serviço de Medicina 1, Centro Hospitalar de Leiria, Leiria, Portugal, ²UGC de Reumatologia, Instituto de Investigación Biomédica de Málaga, Hospital Universitario de Málaga, Universidad de Málaga, Málaga, Spain, ³Centre for Rheumatology, London, United Kingdom
Background/Purpose: To characterize the frequency of thrombocytopenia in SLE and determine its time of onset during the course of the disease, severity and impact on mortality.Methods: This…
Abstract Number: 2022 • 2019 ACR/ARP Annual Meeting
Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms
Erika Hubbard¹, Michelle Catalina ², Sarah Heuer ¹, Prathyusha Bachali ², Nicholas Geraci ³, Peter Lipsky ³ and Amrie Grammer ¹, ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Arthritis is a common manifestation of SLE and the ability of a new lupus therapy often depends on its ability to suppress joint inflammation.…
Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…
Abstract Number: 671 • 2019 ACR/ARP Annual Meeting
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G Hanly¹, Qiuju Li ², Li Su ³, Murray Urowitz ⁴, Caroline Gordon ⁵, Sang-Cheol Bae ⁶, Juanita Romero-Diaz ⁷, Jorge Sanchez-Guerrero ⁸, Sasha Bernatsky ⁹, Ann E Clarke ¹⁰, Daniel J Wallace ¹¹, David A Isenberg ¹², Anisur Rahman ¹³, Joan Merrill ¹⁴, Paul Fortin ¹⁵, Dafna Gladman ¹⁶, Ian Bruce ¹⁷, Michelle Petri ¹⁸, Ellen M Ginzler ¹⁹, MA Dooley ²⁰, Kristjan Steinsson ²¹, Rosalind Ramsey-Goldman ²², Asad A Zoma ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Munther A Khamashta ²⁶, Graciela Alarcón ²⁷, Elisabet Svenungsson ²⁸, Ronald F Van Vollenhoven ²⁹, Cynthia Aranow ³⁰, Meggan Mackay ³¹, Guillermo Ruiz-Irastorza ³², Manuel Ramos-Casals ³³, S Sam Lim ³⁴, Murat Inanc ³⁵, Kenneth C Kalunian ³⁶, Soren Jacobsen ³⁷, Christine Peschken ³⁸, Diane Kamen ³⁹, Anca Askanase ⁴⁰, Chris Theriault ¹ and Vernon Farewell ², ¹Dalhousie University, Halifax, NS, Canada, ²University of Cambridge, Cambridge, United Kingdom, ³Universidy of Cambridge, Cambridge, United Kingdom, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁸Toronto Western Hospital, Toronto, ON, Canada, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹²Centre for Rheumatology, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, ¹⁵Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁶Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹State University of New York Downstate Medical Center, Brooklyn, NY, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Landspitali, University Hospital, Reykjavik, Iceland, ²²Northwestern University, Chicago, IL, ²³University of Glasgow, East Kilbride, United Kingdom, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶King's College London School of Medicine, London, United Kingdom, ²⁷University of Alabama at Birmingham, Birmingham, ²⁸Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²⁹Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³⁰Feinstein Institute for Medical Research, Manhasset, NY, ³¹Feinstein Institute for Medical Research, New York, ³²Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ³³Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³⁴Emory University, Atlanta, GA, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶UC San Diego School of Medicine, LaJolla, CA, ³⁷Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁸University of Manitoba, Winnipeg, Canada, ³⁹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ⁴⁰Columbia University Medical Center, New York, NY
Background/Purpose: Although there is a large body of work on central nervous system (CNS) disease in SLE patients, involvement of the peripheral nervous system (PNS)…
Abstract Number: 1017 • 2019 ACR/ARP Annual Meeting
The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus
Katherine Owen¹, Bryce Aidukaitis ¹, Adam Labonte ¹, Michelle Catalina ¹, Prathyusha Bachali ¹, Nicholas Geraci ², Miranda Marion ³, Hannah Ainsworth ⁴, kip Zimmerman ³, Timothy Howard ⁴, Carl Langefeld ⁴, Peter Lipsky ² and Amrie Grammer ⁵, ¹AMPEL Biosolutions and the RILITE research institute, Charlottesville, VA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Wake Forest School of Medicine, Winston-Salem, NC, ⁴Wake Forest School of Medicine, Winston-Salem, ⁵AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disorder with a prominent genetic component. Evidence has shown that individuals of African-Ancestry (AA) experience the…
Abstract Number: 1578 • 2019 ACR/ARP Annual Meeting
Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ³, ¹University Health Network, University of Toronto, Toronto, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteonecrosis (ON) complicates approximately 15-20% of patients with systemic lupus erythematosus (SLE) on an average of six years after diagnosis. However, a small subgroup…
Abstract Number: 2023 • 2019 ACR/ARP Annual Meeting
Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways
MIKHAIL OLFERIEV¹, David Fernandez ², Dina Greenman ¹, Mary Peng ¹, Kyriakos Kirou ¹ and Mary Crow ¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Mary Kirkland Center for Lupus Research, New York, NY
Background/Purpose: The female predisposition for development of multiple autoimmune diseases is well recognized. The female to male ratio reaches a maximum during the reproductive years…
Abstract Number: 2820 • 2019 ACR/ARP Annual Meeting
Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production
Milena Vukelic¹, Nobuya Yoshida ², Masataka Umeda ³, Seo Yeon Orite ³, Rhea Bhargava ³, Michihito Kono ⁴, Irina Gavanescu-Stockton ³, Ryo Hisada ³ and George Tsokos ², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is disease characterized by an imbalance between pro-inflammatory (such as Th1 and Th17) and regulatory cells (Tregs). Th1 and Th17…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].